# Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

> **NCT07264569** · PHASE1,PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Meningeal Metastasis

## Interventions

- **BIOLOGICAL:** BioTTT001 injection

## Key facts

- **NCT ID:** NCT07264569
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264569, "Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT07264569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*